b3cnewswireAugust 22, 2020
Tag: Byondis , Appointment , Chief Financial Officer
August 22, 2020
Byondis B.V. (formerly Synthon Biopharmaceuticals B.V.) is pleased to announce the appointment of Robbert Van Heekeren as chief financial officer. Mr. Van Heekeren will assume this role on September 1, operating out of Byondis’ headquarters in Nijmegen.
"We are excited to have Robbert join Byondis. He complements our entrepreneurial and inquisitive culture, as well as the talents of our existing management team. Combined with his broad global experience, extensive financial knowledge and clear focus on delivering results, we are convinced Robbert is the right choice to support our further growth," said Byondis CEO Marco Timmers, Ph.D.
“I look forward to joining Byondis’ leadership team. Having played similar roles in related industries and circumstances, I believe that together, we can further our finance strategy so that the company can continue its important work of building a portfolio of next generation medicines for patients with high unmet needs," commented Van Heekeren.
Van Heekeren joins Byondis with nearly 25 years of international management experience in corporate and operational finance, most recently as board member and co-owner of Odyssee Mobile and as an independent corporate finance advisor. Previously, Van Heekeren was: management board member, CFO of Kiadis Pharma N.V.; supervisory board member of Proxy Laboratories (later Sinensis Life Sciences); and executive director, head global finance & control at Organon, the former pharmaceutical business unit of AkzoNobel, where he worked in various international management positions. He holds a postgraduate degree in law, mergers and acquisitions from VU University Amsterdam, and a master’s degree in economics, from Tilburg University, and in industrial engineering & management science, from Eindhoven University of Technology, both of which are in The Netherlands.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: